Thursday, May 28, 2015 8:12:51 AM
I totally agree with what you are saying, DO NOT GET ME WRONG! I believe NBS will eventually be worth a lot more than it is today. I do not understand how the PPS can constantly go down! They have had good news after good news and have gotten nowhere. The next catalyst will be the name change and we will then figure that out, then we have Japan on our heels! ROFLMAO where will we be after that?? We bought CSC (NBS20)How much did we buy that for?? I think I may be wrong but wasn't it equivalent to $5 a share and have dropped $3 a share?? LOL PCT is worth more than $2 a share by its self! We had good results on NBS10 and we dropped?? It just does not make sense.
Recent LSTA News
- Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. • GlobeNewswire Inc. • 03/06/2026 11:15:05 PM
- Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide • GlobeNewswire Inc. • 01/27/2026 01:00:00 PM
- All-Cash Buyout Sparks Breakout Move in Biotech Name • AllPennyStocks.com • 01/21/2026 04:14:37 PM
- Lisata Therapeutics surges on Kuva Labs takeover proposal carrying hefty premium • IH Market News • 01/21/2026 03:41:11 PM
- Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer • GlobeNewswire Inc. • 01/21/2026 12:00:00 PM
- Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/06/2025 09:05:00 PM
- Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’ • GlobeNewswire Inc. • 11/06/2025 01:00:00 PM
- Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent • GlobeNewswire Inc. • 11/04/2025 09:00:00 PM
- Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 • GlobeNewswire Inc. • 10/30/2025 12:00:00 PM
- Lisata Therapeutics to Present at LD Micro Main Event XIX • Newsfile • 10/13/2025 12:00:00 PM
- Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement • GlobeNewswire Inc. • 10/08/2025 12:30:00 PM
- Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial • GlobeNewswire Inc. • 09/29/2025 12:00:00 PM
- Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 09/02/2025 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2025 08:13:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2025 08:09:29 PM
- Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/07/2025 08:05:00 PM
- Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025 • GlobeNewswire Inc. • 07/31/2025 12:00:00 PM
- Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update • GlobeNewswire Inc. • 07/17/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2025 12:00:44 PM
- Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide • GlobeNewswire Inc. • 07/15/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/26/2025 12:38:40 PM
- Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer • GlobeNewswire Inc. • 06/26/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2025 01:13:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2025 08:02:11 PM
- Lisata Therapeutics to Present at the 2025 BIO International Convention • GlobeNewswire Inc. • 06/11/2025 12:30:00 PM
